Linking inflammation and cardiovascular disease: the emerging role of lipoprotein-associated phosphoplipase A2
Article Sidebar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Main Article Content
https://orcid.org/0000-0003-0971-6710
Abstract
Over the past decades, inflammation has been recognized as a key contributor to the development of atherosclerosis, prompting extensive research. Numerous inflammatory markers have demonstrated predictive value for both initial and recurrent coronary events in individuals with or without established coronary vascular disease (CVD). Among these, lipoprotein-associated phospholipase A2 (Lp-PLA2) has garnered significant attention. Lp-PLA2 may be involved in the atherosclerotic process and contribute to plaque destabilization through its inflammatory activity within atherosclerotic lesions. Lipoprotein-associated phospholipase A2 (Lp-PLA2), a recently identified cardiovascular-specific inflammatory mediator, is closely associated with the onset and progression of cardiovascular events. This review explores the potential of Lp-PLA2 as both a risk marker and a therapeutic target in CVD. Elevated levels of Lp-PLA2 mass and activity have been linked to an increased risk of CVD in both the general population and patients with pre-existing disease. However, it remains uncertain whether incorporating Lp-PLA2 measurements into risk prediction models significantly enhances risk stratification beyond traditional cardiovascular risk factors. Additionally, the failure of darapladib, a potent and selective Lp-PLA2 inhibitor, to reduce CVD events in major randomized, placebo-controlled trials suggests the importance of ongoing research to fully understand its functions and develop effective strategies for CVD prevention and treatment.
Article Details
Keywords:
References
Zhang H, Gao Y, Wu D, Zhang D. The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease. BMC Cardiovasc Disord. 2020 Jun 16;20(1):295. https://doi.org/10.1186/s12872-020-01580-4.
Wang KY, Chen YC, Chen JY, Loke SS, Yeh WC, Li WC. Correlation Between Lipoprotein-Related Phospholipase A2 and Metabolic Syndrome. Int J Gen Med. 2023 Dec 22;16:6041-6049. https://doi.org/10.2147/ijgm.s437397
Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: The story continues. Med Res Rev. 2020 Jan;40(1):79-134. https://doi.org/10.1002/med.21597
Yang L, Liu Y, Wang S, Liu T, Cong H. Association between Lp-PLA2 and coronary heart disease in Chinese patients. J Int Med Res. 2017 Feb;45(1):159-169. https://doi.org/10.1177/0300060516678145
Chen J, Zhang H, Li L, Zhang X, Zhao D, Wang L, Wang J, Yang P, Sun H, Liu K, Chen W, Li L, Lin F, Li Z, Chen YE, Zhang J, Pang D, Ouyang H, He Y, Fan J, Tang X. Lp-PLA2 (Lipoprotein-Associated Phospholipase A2) Deficiency Lowers Cholesterol Levels and Protects Against Atherosclerosis in Rabbits. Arterioscler Thromb Vasc Biol. 2023 Jan;43(1):e11-e28. https://doi.org/10.1161/atvbaha.122.317898
Kurniawan LB, Rampo H, Soraya GV, Adnan E, Esa T, Widaningsih Y, Bahrun U, Arif M. Effect of obesity, glucose control, lipid profiles, and blood pressure on Lp-PLA2 levels in type 2 diabetes mellitus patients. Obesity Med. 2021;22:100318. https://doi.org/10.1016/j.obmed.2021.100318
Jakubiak GK, Osadnik K, Lejawa M, Osadnik T, Goławski M, Lewandowski P, Pawlas N. “Obesity and Insulin Resistance” Is the Component of the Metabolic Syndrome Most Strongly Associated with Oxidative Stress. Antioxidants (Basel). 2021 Dec 29;11(1):79. https://doi.org/10.3390/antiox11010079
Younus A, Humayun C, Ahmad R, Ogunmoroti O, Kandimalla Y, Aziz M, Malik R, Saand AR, Valdes C, Badlani R, Younus MA, Ali SS, Chen Y, Nasir K. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: A systematic review. J Clin Lipidol. 2017 Mar-Apr;11(2):328-337. https://doi.org/10.1016/j.jacl.2017.02.005
Mourouzis K, Siasos G, Oikonomou E, Zaromitidou M, Tsigkou V, Antonopoulos A, Bletsa E, Stampouloglou P, Vlasis K, Vavuranakis M, Tousoulis D. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease. Lipids Health Dis. 2021 Feb 14;20(1):12. https://doi.org/10.1186/s12944-021-01438-4
Zhang J, Xu DL, Liu XB, Bi SJ, Zhao T, Sui SJ, Ji XP, Lu QH. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis. Yonsei Med J. 2016 Mar;57(2):321-7. https://doi.org/10.3349/ymj.2016.57.2.321
Fras Z, Tršan J, Banach M. On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management. Arch Med Sci. 2020 Aug 20;17(4):954-964. https://doi.org/10.5114/aoms.2020.98195
Sairam SG, Sola S, Barooah A, Javvaji SK, Jaipuria J, Venkateshan V, Chelli J, Sanjeevi CB. The role of Lp-PLA2 and biochemistry parameters as potential biomarkers of coronary artery disease in Asian South-Indians: a case-control study. Cardiovasc Diagn Ther. 2017 Dec;7(6):589-597. https://doi.org/10.21037/cdt.2017.08.13
Li D, Zhao L, Yu J, Zhang W, Du R, Liu X, Liu Y, Chen Y, Zeng R, Cao Y, Zeng Z, Zhao Z, Wu J. Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis. Clin Chim Acta. 2017 Feb;465:22-29. https://doi.org/10.1016/j.cca.2016.12.006
Zhai Y, Cao X, Liu S, Shen Y. The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy. Ann Med. 2023;55(2):2230446. https://doi.org/10.1080/07853890.2023.2230446
Dua P, Mishra A, Reeta KH. Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection. Biomark Med. 2022 Jul;16(10):821-832. https://doi.org/10.2217/bmm-2021-1129
Wu L, Shao P, Gao Z, Zhang S, Ma J, Bai J, Wei Y. Homocysteine and Lp-PLA2 levels: Diagnostic value in coronary heart disease. Medicine (Baltimore). 2023 Nov 17;102(46):e35982. https://doi.org/10.1097/MD.0000000000035982
Diaconu A, Coculescu BI, Manole G, Vultur H, Coculescu EC, Stocheci CM, Tudorache IS, Dincă AL, Dincă VG. Lipoprotein-associated phospholipase A2 (Lp-PLA2) – possible diagnostic and risk biomarker in chronic ischaemic heart disease. J Enzyme Inhib Med Chem. 2021 Dec;36(1):68-73. https://doi.org/10.1080/14756366.2020.1839447
Li J, Cao T, Wei Y, Zhang N, Zhou Z, Wang Z, Li J, Zhang Y, Wang S, Wang P, Cheng N, Ye L, Li M, Yu Y, Ding C, Tan Z, Zhan B, He Q, Bao H, Wu Y, Liu L, Li J, Xu X, Cheng X, Huang X. A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT). Dis Markers. 2021 Aug 9;2021:6258865. https://doi.org/10.1155/2021/6258865
Garg PK, Arnold AM, Hinckley Stukovsky KD, Koro C, Jenny NS, Mukamal KJ, Criqui MH, Furberg CD, Newman AB, Cushman M. Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):750-6. https://doi.org/10.1161/atvbaha.115.306647
Ueshima H, Kadowaki T, Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Sekikawa A, Kadota A, Kadowaki S, Nakamura Y, Miyagawa N, Okamura T, Kita Y, Takashima N, Kashiwagi A, Maegawa H, Horie M, Yamamoto T, Kimura T, Kita T; ACCESS and SESSA Research Groups. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis. 2016 Mar;246:141-7. https://doi.org/10.1016/j.atherosclerosis.2015.12.027
Capoulade R, Mahmut A, Tastet L, Arsenault M, Bédard É, Dumesnil JG, Després JP, Larose É, Arsenault BJ, Bossé Y, Mathieu P, Pibarot P. Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study. JACC Cardiovasc Imaging. 2015 Jan;8(1):26-33. https://doi.org/10.1016/j.jcmg.2014.09.016
Nazerian P, Mueller C, Soeiro AM, Leidel BA, Salvadeo SAT, Giachino F, Vanni S, Grimm K, Oliveira MT Jr, Pivetta E, Lupia E, Grifoni S, Morello F; ADvISED Investigators. Diagnostic Accuracy of the Aortic Dissection Detection Risk Score Plus D-Dimer for Acute Aortic Syndromes: The ADvISED Prospective Multicenter Study. Circulation. 2018 Jan 16;137(3):250-258. https://doi.org/10.1161/circulationaha.117.029457
Han L, Zhong C, Bu X, Xu T, Wang A, Peng Y, Xu T, Wang J, Peng H, Li Q, Ju Z, Geng D, Zhang Y, He J; CATIS investigation groups. Prognostic value of lipoprotein-associated phospholipase A2 mass for all-cause mortality and vascular events within one year after acute ischemic stroke. Atherosclerosis. 2017 Nov;266:1-7. https://doi.org/10.1016/j.atherosclerosis.2017.09.013
Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Gareeb AI, Lugnier C. Statins Therapy Improves Acute Ischemic Stroke in Patients with Cardio-metabolic Disorders Measured by Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): New Focal Point. Neurol India. 2021 Nov-Dec;69(6):1637-1644. https://doi.org/10.4103/0028-3886.333482
Dong L, Tong J, Fan S. Association between the serum lipoprotein-associated phospholipase A2 level and acute coronary syndrome. Cardiovasc J Afr. 2023 Nov-Dec 23;34(5):273-277. https://doi.org/10.5830/CVJA-2022-056.
Zhang S, Wang J, Chen S, Zhang Y, He R, Wang X, Ding F, Hu W, Dai Y, Lu L, Zhang R, Ni J, Chen Q. Serum levels of lipoprotein-associated phospholipase A2 are associated with coronary atherosclerotic plaque progression in diabetic and non-diabetic patients. BMC Cardiovasc Disord. 2024 May 14;24(1):251. https://doi.org/10.1186/s12872-024-03931-x
De Stefano A, Mannucci L, Tamburi F, Cardillo C, Schinzari F, Rovella V, Nisticò S, Bennardo L, Di Daniele N, Tesauro M. Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419827154. https://doi.org/10.1177/2058738419827154
Yin YJ, Chen YC, Xu L, Zhao XH, Song Yang. Relationship of lipoprotein-associated phospholipase A2(Lp-PLA2) and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention. Int J Cardiol Heart Vasc. 2020 May 26;28:100541. https://doi.org/10.1016/j.ijcha.2020.100541
McConnell JP, Hoefner DM. Lipoprotein-associated phospholipase A2. Clin Lab Med. 2006 Sep;26(3):679-97, vii. https://doi.org/10.1016/j.cll.2006.06.003
Gregson JM, Freitag DF, Surendran P, Stitziel NO, Chowdhury R, Burgess S, Kaptoge S, Gao P, Staley JR, Willeit P, Nielsen SF, Caslake M, Trompet S, Polfus LM, Kuulasmaa K, Kontto J, Perola M, Blankenberg S, Veronesi G, Gianfagna F, Männistö S, Kimura A, Lin H, Reilly DF, Gorski M, Mijatovic V; CKDGen consortium; Munroe PB, Ehret GB; International Consortium for Blood Pressure; Thompson A, Uria-Nickelsen M, Malarstig A, Dehghan A; CHARGE inflammation working group; Vogt TF, Sasaoka T, Takeuchi F, Kato N, Yamada Y, Kee F, Müller-Nurasyid M, Ferrières J, Arveiler D, Amouyel P, Salomaa V, Boerwinkle E, Thompson SG, Ford I, Wouter Jukema J, Sattar N, Packard CJ, Shafi Majumder AA, Alam DS, Deloukas P, Schunkert H, Samani NJ, Kathiresan S; MICAD Exome consortium; Nordestgaard BG, Saleheen D, Howson JM, Di Angelantonio E, Butterworth AS, Danesh J; EPIC-CVD consortium and the CHD Exome+ consortium. Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles. Eur J Prev Cardiol. 2017 Mar;24(5):492-504. https://doi.org/10.1177/2047487316682186